CA Patent

CA2736860C — Methods of treatment using single doses of oritavancin

Assigned to Melinta Therapeutics Inc · Expires 2020-04-28 · 6y expired

What this patent protects

Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the cou…

USPTO Abstract

Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described. Also provided are uses of single intravenous doses comprising oritavancin for complete treatment of complicated skin and skin structure infection in a subject.

Drugs covered by this patent

Patent Metadata

Patent number
CA2736860C
Jurisdiction
CA
Classification
—
Expires
2020-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Melinta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.